Study summary

A new potassium-channel pill cut focal seizures by about half

X-TOLE2 trial (azetukalner) · 374 people, phase 3 · Published November 2026, JAMA Neurology

53.2%median drop in monthly seizures with 25 mg, vs 10.4% with placebo

What was tested

Azetukalner, a once-daily pill that opens Kv7 potassium channels to calm overactive nerve cells, or placebo added to existing medicines for 12 weeks in adults with focal seizures who had tried a median of 5 earlier medicines.

What they found

What it means

Likely to be submitted for approval as the first drug in a new class for focal epilepsy.

JAMA Neurol, via PubMed ↗ Trial record NCT05614063 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.